Excientia has teamed up with East China Pharmaceuticals to accelerate the development of anti-tumor drugs through artificial intelligence.

Read: Exscientia and East China Pharmaceuticals, the world's leading research and development company for artificial intelligence (AI), today announced that they have established a partnership to accelerate the discovery of breakthrough innovative therapies for small molecule drugs in the field of oncology.
, Sept. 9, 2020 /XINHUA/ -- Exscientia, the world's leading artificial intelligence (AI) drug research and development company, and East China Pharmaceuticals today announced that they have established a partnership to accelerate the discovery of breakthrough innovative therapies for small molecule drugs in the field of oncology.
project between the two companies is the development of drugs for DNA injury response gene transcription control to treat patients with high mutation frequency of DNA injury repair defects, such as ovarian and breast cancer patients.
the development of small molecule anti-tumor drugs based on resources and advantages in artificial intelligence and drug research and development.
Excientia uses its advanced Centaur ChemistTM AI platform for automated drug development guidance to design new molecules for specific targets, and East China Pharmaceuticals uses research and development resources and management capabilities to rapidly synthesize and test for new rounds of compounds in AI systems.
East China Pharmaceuticals is one of the top 10 listed pharmaceutical companies (SZ.000963) in Forbes 2020, with more than 10,000 employees and annual sales of more than $4 billion.
cooperation will accelerate the strategic transformation of east China Pharmaceutical Innovation Drugs and help Excientia promote AI design innovative drugs globally.
, chairman of East China Pharmaceuticals, said: "This partnership is another important step forward in East China Pharmaceuticals' path to becoming an innovative pharmaceutical company.
we are pleased to have reached this strategic partnership with Excientia and we will use our research and development strengths to make the project a success.
, Ceo of Excientia, said, "We are pleased to have a partnership with East China Pharmaceuticals, an innovative partnership model that is in the strategic interest of Exscientia and East China Pharmaceuticals.
that this is also the beginning of a long-term partnership that will accelerate the development of new drugs for the benefit of patients around the world.
"